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ABSTRACT
Introduction: The benefits of rotavirus (RV)
vaccination in developed countries have
focused on reductions in mortality,
hospitalization and medical visits, and herd
protection. We investigated other aspects
related to RV-induced nosocomial infection,
duration of hospital stay, age shift, and
sustained vaccine impact (VI) over time.
Method: RotaBIS (Rotavirus Belgian Impact
Study; ClinicalTrials.gov identifier,
NCT01563146) annually collects retrospective
data on hospitalization linked to RV testing in
children up to 5 years old from 11 pediatric
wards located all over Belgium. Data from 2005
to 2012 have been split in pre- (2005–2006) and
post-vaccination (2007–2012) period.
Information was collected on age, gender, RV
test result, nosocomial infection caused by RV
and duration of hospital stay.
Results: Over the 6-year period after the
introduction of the RV vaccine, an 85%
reduction in nosocomial infections was observed
(221 in 2005 to 33 in 2012, p\0.001). A
significant reduction of almost 2 days in average
duration of hospital stay per event was observed
overall (7.62 days in 2005 to 5.77 days in 2012,
p\0.001). The difference is mainly explained by
the higher reduction in number of nosocomial
infections. A pronounced age shift (?24%,
p\0.01) of RV nosocomial infection to infants
B2 months old was observed, increasing with
length of post-vaccination period. VI was
maintained over the follow-up (±79% VI per
birth cohort). A decrease was seen depending on
age,85%(95%CI76–91%) in theyoungest to63%
(95% CI 22–92%) in the oldest age group.
Conclusion: The higher reduction in
nosocomial infection may affect the overall
average duration of hospital stay for RV
infection. No change in VI by birth cohort,
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but a reduction by age group was observed.
These findings could be important for
decision-makers considering the introduction
of universal mass RV vaccination programs.
Trial registration: ClinicalTrials.gov identifier,
NCT01563146.
Funding: GlaxoSmithKline Biologicals SA
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INTRODUCTION
Rotavirus (RV) infection is a well-known cause of
acute gastro-enteritis leading to severe diarrhea
in small children. It shows a seasonal pattern in
the more temperate climates, resulting in
epidemic peaks during winter and spring [1, 2].
As a result pediatricwards areoftenoverwhelmed
with a high bed occupancy rate due to diarrheal
disease [3]. High rates of infant hospitalization
for other conditions that occur in the same
period, such as bronchiolitis, can further
compound the problem of overcrowding. [4].
The use of vaccines could help to improve
management of this recurrent annual health
care problem [5]. Different vaccines have
demonstrated a high efficacy against severe
disease in infants and young children. Two
vaccines are currently on the market at the
global level, a two-dose vaccine RotarixTM (GSK,
Rixensart, Belgium) [6, 7] and a three-dose
vaccine RotateqTM (Merck and Co. Inc,
Whitehouse Station, New Jersey, United States)
[8]. Belgium was one of the first countries in
Europe to introduce the RV vaccine with a
co-payment scheme [9]. The vaccines have been
reimbursed since November 2006 (first Rotarix
and subsequently Rotateq, 1 year later) [10]. A
high vaccine uptake (above 85%) in the first year
of introduction of RV vaccination has been
maintained over the years [9, 11]. To date, the
vaccination program has had more than 7 years’
impact on the local health care system.
In 2007, we initiated the RotaBIS (Rotavirus
Belgian Impact Study) study. This project
annually collects retrospective data for the
past year on RV testing linked to the
hospitalization of children aged under 5 years
in 11 hospitals located all over Belgium [9].
Based on RotaBIS, we reported last year on the
general effect the vaccines have had on
hospitalization, expressing the number of
positive test results for RV by age and year and
comparing the pre- versus the post-vaccination
periods [12]. The results demonstrated sustained
vaccine-associated protection over time, i.e., a
reduction of RV-related hospitalizations
observed after 7 years of around 75%, with a
high herd protection level of 26.5% in the first
year of the vaccine introduction. In addition,
data on many other parameters were
systematically collected during the whole
follow-up period of the RotaBIS project. These
additional data are now analyzed in the present
study to address further questions on the
impact of the vaccine on RV-induced
nosocomial infections [13], the average
duration of hospital stay being for a certain
period a surrogate marker for disease severity
[14], a potential more pronounced age shift of
RV disease after the introduction of the vaccine
[15], and the sustainability of the vaccine
impact (VI) over time [12].
Based on the data available since 2005, we
have attempted to investigate whether the total
value of the RV vaccine extends beyond the
reduction in hospitalization rate and the
generation of a high level of herd protection
in the early period of the vaccine introduction.
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Information on these additional questions
could help to test earlier conclusions that RV
vaccination could improve quality of care




The RotaBIS is a retrospective hospital database
study (ClinicalTrials.gov identifier,
NCT01563146) previously published [9]. The
study annually collects retrospective data on
hospitalization linked to RV testing in children
aged up to 5 years from 11 pediatric wards
located all over Belgium, which represent
around 450 pediatric beds (16% of the total
available in the country). Data from 2005 to
2012 have been split in pre- (2005–2006) and
post-vaccination (2007–2012) period
(reimbursement of the vaccine was introduced
in November 2006) [17].
The information assembled was the
following: center code, age, gender, date of
sampling, RV test results, date of hospital
admission and discharge, clinical outcome
(ambulatory or hospitalized), and evidence of
nosocomial infection. An RV infection was
identified as nosocomial if the stool sample
tested was RV positive 48 h or more after the
day of non-diarrhea-related hospital admission.
The duration of nosocomial infection was
reported as the full period of hospitalization
and the period from which the rotavirus test
was positive. No information on the RV
vaccination status of the child was available.
The data were anonymized before any analysis
occurred. All procedures followed were in
accordance with the ethical standards of the
responsible committee in each center. Approval
for the study was obtained from each center
each year the data were collected.
Data Analysis
Among the RV tests performed in the children
admitted in these hospitals during the evaluation
period, the proportion of RV-positive tests was
calculated for each participating center, per
month and per year, for six different age groups:
0–2 months, [2–12 months, [1–2 years,
[2–3 years, [3–4 years, and [4–5 years. Data
among the sub-group of children aged
B2 months were also analyzed because, even if
they were too young for vaccination, they could
experience a herd protection effect after the
vaccine was introduced.
The data were analyzed per year (2005–2012)
for the number of RV-induced nosocomial
infections during the peak periods of January
until the end of May for the six age groups. The
data were also compared per year relative to
their distribution by age group: pre-vaccination
versus post-vaccination (first year, second year,
nth year, …, sixth year post-vaccination). The
average duration of hospital stay for the
treatment of RV diarrhea per year and per age
group is reported. The cumulative proportion of
RV patients as a function of the duration of
their hospital stay per year is also evaluated. It
allows the identification of the proportion of
patients with a very long hospital stay. These
patients should be considered separately, as
their long stay is more influenced by other
diseases for which they were hospitalized than
by the rotavirus infection they acquired during
their stay. The hypothesis that the introduction
of the vaccine may have reduced the overall
average duration per rotavirus disease event and
per source of infection (nosocomial and
community-acquired) has been tested. The
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duration of the RV-induced nosocomial
infection events were split into a pre- and a
post-sample period. Finally, the analysis
estimated the impact of vaccination on the
overall bed occupancy during the peak period
by source of infection (community-acquired
and nosocomial) for the year 2005
(pre-vaccination) and 2012 (post-vaccination).
The VI is reported over time on RV-induced
hospitalizations by age group (i) and birth
cohort (y). A full definition for calculating the
VI has been presented in the previous article on
the RotaBIS study [12], but here the relative
value is measured by calculating the ratio of
hospitalization rate post-vaccination (Hospviy)
to the hospitalization rate for the same age
groups pre-vaccination for one reference year,
2005 (Hospnvi2005), using the formula
(VI = Hospviy/Hospnvi2005 - 1). We only
investigated the direct VI and did not consider
age groups that are under the influence of herd
protection. This analysis should indicate
whether the VI is maintained over time by
year and age.
To measure the relative importance of the
disease as a function of age that may shift over
time after vaccine introduction, we calculated
the proportional distribution of the disease over
the different age groups in each year. We then
plotted on a graph the proportional results per
age group in each year and observed shifts in
those proportions.
Assumptions
A few assumptions underlie the comparison of
the annual number of RV-positive tests. One
assumption is that the catchment area of each
of the participating centers remained the same
across the whole observation period of 8 years.
Another assumption is that no change
occurred during the period in the disease
management behavior of testing children up
to 5 years old for RV disease. This means that if
fewer tests were performed after the
introduction of the vaccine, this is mainly
due to fewer suspected cases presenting to the
hospital unit and not to a change in behavior
of physicians who may have decided to
perform RV tests less frequently after vaccine
introduction. Therefore, the most relevant
comparison between the years is the
accumulated number of RV-positive tests and
not the proportion of RV-positive tests per
year. A third assumption is that during the
whole observation period of 8 years there was
no change in the criteria for hospitalizing
patients with rotavirus disease, given that
hospital beds were becoming unoccupied
during the peak period after the vaccine had
been introduced. Reduced bed occupancy
could become an incentive for trying to get
those beds occupied by changing the
admission criteria.
Statistics
Results were tested for statistical significance
using Chi-square tests for the trend of
proportional and absolute data over the years.
Non-parametric rank testing (Kruskal–Wallis
test and Mann–Whitney test) or ANOVA
testing after a normality check of the data
distribution was used for comparing the
values. If not normally distributed, log-norm
transformation was applied. 95% confidence
intervals (CI) were measured for VI values using
the Wilson method [18]. The statistical tests
were performed with GraphPad Prism 6.2 for
Windows, GraphPad Software, La Jolla
California USA, www.graphpad.com. The cut-
off value for significance was p = 0.05.
512 Infect Dis Ther (2016) 5:509–524
RESULTS
RV-induced Nosocomial Infections
Figure 1 and Table 1 present the results for
RV-induced nosocomial infection by year.
There is a decrease observed in RV-induced
nosocomial infections from 2005 (n = 221) to
2012 (n = 33) (Chi-square test for trend: 10.96;
p\0.001), with a relative reduction of 85%
when comparing the two extreme years. The
relative contribution of nosocomial RV
infections to the total number of RV
hospitalizations also dropped from 17% in
2005 to 10% in 2012 (Table 1) (Chi-square for
relative trend = 11.13, p\0.001). The peak
observed in April 2011 in Fig. 1 reflects an
unusually high number of cases from a single
center during that month (8/21 cases, 38% of
the total).
Hospital Bed Occupancy and Length
of Stay
The above data indicated a dramatic reduction
in the number of nosocomial infections after
the introduction of the vaccine. We
investigated the contribution of rotavirus to
bed days occupied during the peak period of
rotavirus disease pre-vaccination and a few
years after the vaccine was introduced. Table 2
summarizes the collected numbers for 2005
pre-vaccination and 2012 post-vaccination
































































































Fig. 1 Spread of RV-induced nosocomial infections over the years. Dotted red line indicates when RV vaccine was
reimbursed. RV rotavirus
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in the reduced proportions of 2005 compared
with 2012, Chi-square, df = 3017, p\0.001).
The denominator is different for the two years,
as 11 more pediatric beds were available in
2012. The contribution of rotavirus disease to
the overall bed occupancy varied per month
during the pre-vaccination period, with peaks
up to 12% of the pediatric beds. Nosocomial
infections could have a peak contribution
that occurs independently of the
community-acquired peak. The impact of the
vaccine on bed occupancy is that 6 years after










2005 1103 221 1324 17
2006 1265 134 1399 10
2007 694 143 837 17
2008 462 69 531 13
2009 318 45 363 12
2010 336 50 386 13
2011 359 53 412 13
2012 294 33 327 10
RV rotavirus
Table 2 Bed-days occupied pre- (2005) and post-vaccination (2012) during the peak-period overall and by source of
infection (community-acquired and nosocomial)








2005 1 13,640 930 (6.8%) 541 (4.0%) 389 (2.9%)
2 12,320 1433 (11.6%) 1101 (8.9%) 322 (2.7%)
3 13,640 1649 (12.1%) 1288 (9.4%) 361 (2.6%)
4 13,200 543 (4.1%) 449 (3.4%) 94 (0.7%)
5 13,640 280 (2.1%) 217 (1.6%) 63 (0.5%)
Total 66,440 4835 (7.3%) 3596 (5.4%) 1239 (1.9%)
2012 1 13,981 113 (0.8%) 57 (0.4%) 56 (0.4%)
2 12,628 137 (1.1%) 97 (0.8%) 40 (0.3%)
3 13,981 145 (1.0%) 113 (0.8%) 32 (0.2%)
4 13,530 288 (2.1%) 262 (1.9%) 26 (0.2%)
5 13,981 168 (1.2%) 145 (1.0%) 23 (0.2%)
Total 68,101 851 (1.2%) 674 (1.0%) 177 (0.3%)
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its introduction, close to 3984 bed days, or 6%,
are available during the peak period per year,
which can be used for purposes other than
rotavirus disease.
Overall Average Duration
The overall average duration of a hospital stay
for an RV-induced diarrhea event also decreased
from 7.62 to 5.77 days, which is close to a 2-day
average gain per event, (ANOVA testing after
log-normal transformation, F(7, 4389) = 7.706,
p\0.001) (see Fig. 2). During the 5 most recent
years, a clear trend reduction in average
duration was observed, with the standard
errors of the mean also becoming smaller
(ANOVA testing after log-normal
transformation, F(4, 1544) = 8.599, p\0.001).
The spread of hospital duration was heavily
skewed to the right (long tail to the right)
pre-vaccination in 2005, as shown in Fig. 3.
After the introduction of the vaccine this
skewness to the right became much less
pronounced, as seen for the year 2012.
By Source of Infection
When the hospital duration is split by source of
infection (community-acquired or nosocomial),
the changes over the years in average duration
were much less pronounced (see Table 3).
However, the average difference in duration
between community-acquired (non-nosocomial)
and nosocomial RV-associated hospital stay
exceeded 10 days when the total hospital
length of stay was considered for nosocomial
infection. If only the RV-specific period of
nosocomial infection was considered, the
average difference was reduced to 4–5 days,
with average durations of 5 and 10 days,
respectively, for community-acquired and
nosocomial RV-associated hospital stay (see
Table 3).
Age Shift
Age had an influence on the duration of
RV-induced hospital stay, especially for
nosocomial infection, as shown in Fig. 4
[Kruskal–Wallis (K–W) rank test, 5 groups, K–W
stats = 41.45, p\0.001]. The average duration
declined with increasing age and this trend was
presentwith orwithout the vaccine introduction.
In addition, we observed an absence of
RV-induced nosocomial infections in the older
age groups after the vaccine introduction.
Post-vaccination (2012), the age group
relatively more affected by RV-induced
nosocomial infections is the group of young
infants (\2 months old), who are unvaccinated
(48–24% = ?24%) (Fig. 5) (Chi-square test for
trend: 6.737; p\0.01). The relative importance
increases the longer the observation period
post-vaccine introduction lasts.
Vaccine Impact Over Time
Figure 6 shows the observed VI on RV-induced
hospitalization over time by birth cohort and
age group when compared with the
pre-vaccination period. No trend for reduced
VI was seen over time within each separate age
























Fig. 2 Overall average duration in days for a hospital
rotavirus event over time with linear time trend line for
the last 5 years and standard errors of the mean
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average VI per year, and the 95% CI of the mean
calculated for each year overlaps between the
lowest and highest average value. However,
there was a trend in the reduction of average
VI across age groups: 85% in the group aged
3–12 months; 80% in the group aged 1–2 years;
79% in the group aged 2–3 years; 74% in the
group aged 3–4 years; and 63% in the group
aged 4–5 years. The 95% CI calculated for each
age group also overlaps between the highest and
the lowest value because of the small numbers
in the older age groups (95% CI 76–91% in the
highest number of the youngest age group and
22–92% in the oldest age group). In the two
oldest age groups, the denominators are small
(34 and 10 cases, respectively), leading to a
statistically non-significant difference between
the age groups. Moreover, hospitalization
events are driven by local policy in managing
the disease in older children: only 2 of the 11
centers have increased hospitalization rates in
the older age groups (Data on file, GSK
Vaccines, Wavre, Belgium).
DISCUSSION
The benefits of RV vaccination initially reported
in the literature focused on the specific
mortality reduction, the decrease in
hospitalizations, and the level of herd
protection achieved during the first years of


















Duraon of hospital stay (days) 
2005 2012
Fig. 3 Shift in the spread of duration of all rotavirus-hospital stay pre- (2005) versus post-vaccination (2012)
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2005 1103 4.87 4.80 1 103 4
2006 1265 6.03 11.72 1 187 5
2007 694 5.27 7.98 1 161 4
2008 462 5.90 8.53 1 134 4
2009 318 4.59 2.25 1 23 4
2010 336 4.26 2.66 1 37 4
2011 359 3.96 1.87 1 10 4
2012 294 4.09 1.90 1 16 4
RV-induced nosocomial (full duration)b
2005 221 18.28 25.46 3 209 10
2006 134 12.06 10.52 3 73 9
2007 143 19.92 48.02 2 474 11
2008 69 17.78 20.30 4 125 10
2009 45 29.60 44.58 4 177 12
2010 50 20.81 27.81 4 162 10
2011 53 18.71 24.37 1 137 10
2012 33 16.93 17.36 4 101 12
RV-induced nosocomial (rotavirus-speciﬁc period)c
2005 221 9.21 17.71 1 138 5
2006 134 5.85 7.95 1 64 4
2007 143 9.73 26.30 1 253 5
2008 69 9.00 16.67 1 120 4
2009 45 13.66 23.44 1 112 5
2010 50 10.77 21.89 1 136 4
2011 53 11.20 19.54 1 100 5
2012 33 8.63 9.44 1 45 5
RV rotavirus
a ANOVA testing, after transformation, F(7, 3631) = 4.120, p = 0.0002
b ANOVA testing, after transformation, F(7, 740) = 1.827, p = 0.08
c ANOVA testing, after transformation, F(7, 735) = 1.108, p = 0.35
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in many countries in Europe and worldwide
where vaccination was implemented [19–27].
Important additional vaccine benefits that
could improve QoC in the hospital
environment have been less well documented
and reported. It is known that RV is very
contagious and that strict hygiene measures
cannot always avoid the spread of the virus
[28, 29]. The present study indicates that, with
the introduction of the vaccine, an important
drop of 85% in nosocomial RV infections can be
achieved within a few years, together with a
reduction in the overall average duration of
hospital stay for the disease. It is important to
highlight that this overall number should be
reported, as it is often the first number available
in the absence of being able to differentiate
between community-acquired and nosocomial
infection. However, the shorter hospital stay


























Fig. 4 Comparing the average hospital duration (days) according to age and year (2005 pre- and 2012 post-vaccination) for































Fig. 5 The relative contribution of rotavirus-induced nosocomial infections by age group and by year
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nosocomial infections, which on average have a
much longer duration than the
community-acquired infections, rather than to
a shorter hospital stay specific for
community-acquired RV diarrhea and/or
RV-induced nosocomial infection. The drop in
nosocomial infections and the shorter hospital
stay will benefit young patients who are
admitted to the hospital for reasons other
than diarrhea, as they will now be exposed to
a much lower risk of RV infection after the
introduction of the vaccine. This will benefit
their recovery because the shorter duration of
hospital stay will reduce their risk of exposure to
any other nosocomial infection source in the
hospital environment [16].
Figure 5 shows that after vaccine
introduction the distribution of RV
hospitalization for nosocomial infections
shifted towards the very young age group
where infants are still unvaccinated. This
process increased progressively over the
successive years of the vaccination program
(see the youngest age group in Fig. 5). We,
therefore, evaluated the data on duration of
hospital stay to investigate whether more severe
cases were hospitalized in more recent years
post-vaccination among infants, when
compared with the pre-vaccination period in
the same age group. Figure 7 shows the results
in the group aged \2 months for RV-induced
nosocomial infection and RV-induced
community-acquired diarrhea, comparing the
year 2005 (pre-vaccination) with the year 2012
(post-vaccination, the latest year of the
observation). There was little difference
between 2005 and 2012 in the duration of
hospital stay for RV-induced
community-acquired diarrhea events (the lines
are close together at the left side of the graph).
In contrast, among RV-induced nosocomial



























Fig. 6 Measuring rotavirus vaccine impact by year, birth cohort, and age group
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the frequency of patients with long hospital
stays ([30 days of hospitalization) after the
vaccine was introduced. Figure 7 also shows
the frequency of hospitalizations [30 days in
2005 and 2012, and indicates a reduction of
14% in these long hospitalizations in the
post-vaccine period (2012) compared with the
pre-vaccine period (2005). It suggests a trend to
less severe disease events in very young infants
after the vaccine was introduced. The rank test
(Mann–Whitney U test) did not report a
statistically significant difference in duration
between the two periods, although the median
was 4 days lower for the 2012 data (median:
18 days in 2005 and 14 days in 2012; p = 0.45).
This analysis raises two questions. First,
whether it is rational to include long hospital
stays in the analysis of nosocomial infections, as
those long stays are probably not caused by the
rotavirus infections but more by the primary
cause of hospitalization. The graph may,
therefore, help to identify a reasonable cutoff
for hospitalization lengths that still contribute
to the average duration of the rotavirus
nosocomial infection. In Fig. 7, a cutoff of
25–30 days seems reasonable, although the
results of the cutoff could be different in
different environments. Second, whether there
is a need for earlier vaccination, closer to the
day of birth, as it is mainly in very young
infants that additional benefit of the vaccine
can be expected and where the current disease
burden is particularly concentrated. Further
research is required [30–32].
The question of whether the VI is
maintained over time needs to be answered
cautiously. There are two time dimensions to be
considered in the analysis. One is a horizontal
timeline with annual evaluations of the impact,
and the other is a diagonal timeline as
individuals move to the next year (horizontal
shift) and at the same time grow older (vertical
shift). This is called a cohort analysis versus a
population analysis [33]. When the results are
compared horizontally, good consistency is
observed over time within each age group as
reported in Fig. 6. The overall results for each
annual birth cohort indicate a slight increase in
average VI, but that is due to the last two birth
cohorts where data were not available for all the
age groups as the individuals in these birth
cohorts have not yet attained the older ages.
Considered from a cohort point of view, a
trend of VI decrease was observed by age group
(also reported in Fig. 6). This could be related to
a real decrease in VI, a change in management
of events among the older children, or a change
in testing leading to fewer cases detected and
reported in the older age groups. Essentially,
two centers out of the eleven had a policy to





















cumulave % non-noso 2005
cumulave % noso 2005
Fig. 7 Comparison of the cumulative frequency (%) of
patients as a function of the duration of hospital stay for
rotavirus-induced nosocomial and community-acquired
infection of infants \2 months old for the year 2005
and the year 2012. Red dashed lines indicate the frequency
of hospitalizations[30 days in 2005 and 2012
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the rules of disease management across ages and
centers should be maintained to measure a real
decline in VI, rather than some possible change
in disease or diagnostic management because of
particular pressures.
There are weaknesses in the RotaBIS study,
because it has a retrospective design without
full control of the denominator. In addition,
no rules have been imposed on precisely how
to manage children for hospitalization
independent of age. It could, therefore, be
that the data here observed are not only a
consequence of the vaccination impact but
could also be a result of additional measures
taken in the hospital environment to improve
control of infectious diseases during recent
years. This has consequences when handling
small numbers and reporting relative values,
such as the VI in the age group above 3 years.
However, the highest disease burden is in the
group aged \2 years, and we observed quite
consistent results over time in this group [34].
Finally, information on the vaccination status
of the children when they are hospitalized is
missing from the study. We are working on
ways to collect that information in subsequent
runs of the RotaBIS study in the coming years,
as it is important to know how many of the
hospitalized children were exposed to the
vaccine. However, the attractiveness of the
RotaBIS study is the low burden in collecting
the data, the simple analyses performed and
communicated, which sometimes raise
additional new research questions, and the
opportunity to obtain real-world results that
can be compared with model output
predictions (for instance, related to herd
protection). It gives valuable information on
the disease and whether the vaccine maintains
its impact over time, which will be useful to
decision-makers evaluating RV vaccination
programs.
CONCLUSION
TheRotaBIS study illustrates additional results that
RV vaccination may generate within a hospital
environment, besides reducing the number of
hospitalizations. The new results focus on the
reduction in nosocomial RV infections (-85%),
leading to a shorter duration in hospital stay (on
average \2 days per RV event). Consequently,
better QoC in the hospital environment can be
developed, enhancing better health care delivery
because of the reduction in bed occupancy during
the peak period of rotavirus disease. From the data
analyzed over a 6-year period, the VI was
maintained over time in the younger age groups.
We observed a slight decrease in the older age
groups above 3 years, which could be better
explained by changes in local disease and
diagnostic management rules than by a real
decline in VI.
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